Biopharma company Jazz Pharmaceuticals (NASDAQ: JAZZ) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 2.1% year on year to $1.05 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $4.23 billion at the midpoint. Its non-GAAP loss of $8.25 per share was 32.1% below analysts’ consensus estimates.

Is now the time to buy JAZZ? Find out in our full research report (it’s free).

StockStory’s Take

Jazz Pharmaceuticals’ second quarter saw management attribute performance to solid momentum in its neuroscience portfolio, particularly strong growth from Xywav, offset by near-term challenges in its oncology business. Executives acknowledged competitive dynamics and protocol changes affecting oncology sales, as well as inventory-related impacts on Epidiolex growth. CEO Bruce Cozadd described the period as “a quarter of robust execution in neuroscience, counterbalanced by oncology headwinds,” emphasizing the company’s reliance on new launches and approvals to sustain growth. Management also highlighted ongoing investments in patient education and field initiatives to bolster core products.

Looking forward, Jazz Pharmaceuticals’ updated guidance is grounded in expectations for multiple regulatory catalysts in its oncology pipeline and continued commercial execution in neuroscience. Incoming CEO Renee Gala stated, “My focus is on ensuring a smooth transition and gathering broad input to guide our next phase of growth.” Management expects the approval and launch of dordaviprone, potential label expansion for Zepzelca, and the late-year data readout for zanidatamab to significantly shape revenue and margin trajectories. The company is prioritizing targeted investments in launch preparations and clinical trials, while maintaining a disciplined approach to operational efficiency.

Key Insights from Management’s Remarks

Management identified robust growth in neuroscience, led by Xywav, as the main driver for the quarter, while oncology faced competitive and protocol headwinds. Strategic investments in product launches and pipeline development were prioritized to support future momentum.

• Neuroscience strength: Xywav delivered 13% year-over-year sales growth, attributed to effective patient education campaigns and integrated support services, particularly in idiopathic hypersomnia (IH), where it remains the only FDA-approved therapy. Management credited field teams and nurse educators for improved patient persistence and net adds.
• Epidiolex demand and inventory dynamics: Epidiolex maintained strong underlying demand, though quarterly sales growth was moderated by inventory fluctuations in the U.S. Management expects typical inventory builds in the second half and remains confident in achieving blockbuster status for the product this year.
• Oncology headwinds: The oncology portfolio experienced a modest decline, with Rylaze and Zepzelca impacted by new treatment protocols and increased competition, particularly from tarlatamab in second-line small cell lung cancer. Zepzelca’s near-term pressure is expected to be alleviated by its potential move into first-line maintenance.
• New product launches: The company advanced key pipeline assets, including preparing for the FDA approval and commercial launch of dordaviprone for a rare brain tumor, and initiated a rolling launch of Ziihera in Europe for biliary tract cancer. Management emphasized the potential of these assets to offset oncology declines.
• R&D and operational efficiency: Strategic reductions in SG&A and R&D spending were implemented to prioritize high-impact initiatives, especially in launch activities for dordaviprone and clinical support for zanidatamab. Management highlighted the importance of disciplined capital allocation in a challenging market environment.

Drivers of Future Performance

Jazz Pharmaceuticals’ near-term outlook is shaped by upcoming regulatory milestones in oncology, ongoing investments in launch activities, and operational discipline to manage margin pressures.

• Regulatory catalysts in oncology: Management anticipates multiple key events, including the anticipated FDA approval of dordaviprone for diffuse glioma and potential label expansion for Zepzelca in first-line maintenance for small cell lung cancer. These milestones are expected to significantly influence revenue growth in the second half of the year.
• Sustained neuroscience momentum: The company continues to invest in expanding Xywav and Epidiolex, with a focus on patient education, digital outreach, and support programs to drive adoption and persistence. Management views the potential entry of generic competitors as manageable due to product differentiation and ongoing field activities.
• Cost management and efficiency focus: Jazz is prioritizing spending on high-impact R&D and commercial programs, with targeted reductions in broader SG&A and R&D to mitigate margin pressure from recent losses. The company’s strong cash position supports both pipeline advancement and potential business development opportunities.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be closely tracking (1) progress toward FDA approval and commercial launch of dordaviprone, (2) the outcome of Zepzelca’s label expansion for first-line maintenance use in small cell lung cancer, and (3) the Phase III data readout for zanidatamab in gastroesophageal cancer. Execution on these regulatory and clinical milestones, alongside stabilization of the oncology portfolio and continued growth in neuroscience, will be key indicators of performance.

Jazz Pharmaceuticals currently trades at $115.47, up from $113.05 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.